AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen

by Barry101 | Sep 20, 2021 | Press Release, Uncategorized

OCALA, Fla., Sept. 20, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus...

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction

by Barry101 | Sep 8, 2021 | Press Release, Uncategorized

OCALA, Fla., Sept. 08, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a...

AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

by Barry101 | Aug 25, 2021 | Press Release, Uncategorized

Patients with symptoms of PCCD being treated with Ampligen in the ongoing AMP-511 Early Access Program have reported consistent improvements in cognitive functionOCALA, Fla., Aug. 25, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on...

AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

by Barry101 | Aug 25, 2021 | Press Release, Uncategorized

Patients with symptoms of PCCD being treated with Ampligen in the ongoing AMP-511 Early Access Program have reported consistent improvements in cognitive functionOCALA, Fla., Aug. 25, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on...

AIM ImmunoTech Provides Second Quarter 2021 Business Update

by Barry101 | Aug 17, 2021 | Press Release, Uncategorized

OCALA, Fla., Aug. 17, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.    Second Quarter 2021 Financial Highlights: As of June 30, 2021, AIM had cash,...